REGULATORY MACROPHAGES FOR TREATING ANGIOPATHIES

Abstract

The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro- and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing. Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.

Claims

1. A method of treating micro- or macroangiopathies of lower limbs or inducing wound healing in a subject, comprising administering an immunoregulatory macrophage expressing the markers CD258, DHSR9 and IDO to the subject.

2. The method of claim 1, wherein said macrophage expresses the markers CD258, DHRS9, IDO and TGFβ1.

3. The method of claim 1, wherein said macrophage expresses the markers CD258, DHRS9, IDO, TGFβ1 and PAEP.

4. The method of claim 1, wherein said macrophage expresses the markers CD258, DHRS9, IDO, TGFβ1 and PAEP.

5. The method of claim 1, wherein said macrophage further expresses at least one of the markers selected from the group consisting of macrophage lineage markers CD33, CD33, CD11b and HLA-DR.

6. The method of claim 1, wherein said micro- or macroangiopathies are diabetic micro- or macroangiopathies.

7. The method of claim 1, wherein said micro- or macroangiopathies are diabetic or venous leg ulcers.

8. The method of claim 1, wherein said method comprises the administration of between 1×10.sup.5 to 1×10.sup.7 macrophages to the subject.

9. The method of claim 1, wherein said method comprises the administration of macrophages directly into the ulcer by subcutaneous or intramuscular injection.

10. The method of claim 1, wherein said microangiopathy is selected from the group consisting of angiitis, arteritis, angiodysplasia, atrophy blanche, dermatosclerosis, Determann syndrome, diabetic angiopathy, endangiitis obliterans, erythromelalgia, fibro muscular dysplasia, malum perforans, Mönckeberg Sclerosis, Osler's disease, compartment syndrome, Paget-von-Schroetter syndrome, Raynaud's syndrome, and leg ulcers.

11. The method of claim 1, wherein said macroangiopathy is selected from the group consisting of aneurysm, dissection, atherosclerosis, atherothrombosis, peripheral arterial occlusive disease (PAD), claudicatio intermittens, necrosis and gangrene, vascular malformation, Leriche syndrome, and compression syndrome.

12. The method of claim 1, wherein said subject is afflicted with diabetic mellitus.

13. The method of claim 1, comprising administering to the subject a pharmaceutical composition comprising said immunoregulatory macrophage expressing the markers CD258, DHRS9 and IDO.

14. A pharmaceutical composition comprising an immunoregulatory macrophage expressing the markers CD258, DHRS9, and IDO.

15. The pharmaceutical composition of claim 14, wherein said immunoregulatory macrophage expresses the markers CD258, DHRS9, IDO and TGFβ1.

16. The pharmaceutical composition of claim 14, wherein said immunoregulatory macrophage expresses the markers CD258, DHRS9, IDO, TGFβ1 and PAEP.

17. The pharmaceutical composition of claim 14, wherein said immunoregulatory macrophage expresses the markers CD258, DHRS9, IDO, TGFβ1 and PAEP.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0068] FIG. 1 shows the results of treating leg ulcers in a patient suffering from peripheral artery disease (PAD) by injection of 1×10.sup.7 Mregs.

[0069] FIGS. 2A-2M specifies the phenotype and specialized functional characteristics of human Mregs.

[0070] FIG. 2A shows that strong DHSR9 mRNA expression was detected in Mregs by RT-qPCR, but not comparator macrophage types (n=6; mean±SD).

[0071] FIG. 2B shows the results of immunoblotting demonstrating that DHSR9 protein expression distinguishes Mregs from comparator macrophages.

[0072] FIG. 2C shows expression of TNFSF14/CD258 mRNA in a panel of comparator macrophages quantified by microarray analysis (n=3; mean±SD).

[0073] FIG. 2D shows cell-surface expression of CD258 by human Mregs detected by flow cytometry.

[0074] FIG. 2E illustrates an experimental system to show that direct interaction of naive CD25.sup.− FoxP3.sup.− CD4.sup.+ T cells with human Mregs leads to their conversion into activated CD25.sup.+ FoxP3.sup.+ CD4.sup.+ T cells.

[0075] FIG. 2F shows iTregs generated from naive CD25.sup.− FoxP3.sup.− CD4.sup.+ T cells through interaction with human Mregs when cocultured in a 1:2 ratio.

[0076] FIG. 2G shows expression of IDO mRNA in a panel of comparator macrophages quantified by microarray analysis (n=3; mean±SD).

[0077] FIG. 2H shows expression of IDO by human Mregs detected by intracellular staining and flow cytometry.

[0078] FIG. 2I shows expression of PAEP mRNA in a panel of comparator macrophages quantified by microarray analysis (n=3; mean±SD).

[0079] FIG. 2J shows that neutralisation of secreted PAEP protein with a neutralising antibody against PAEP led to a significant reduction in iTreg generation.

[0080] FIG. 2K shows expression of TGFβ1 mRNA in a panel of comparator macrophages quantified by microarray analysis (n=3; mean±SD).

[0081] FIG. 2L shows 24-hour secretion of TGFβ1 by human Mregs and comparator macrophages.

[0082] FIG. 2M shows a comparison of Mregs with PCMOs in terms of Treg induction.

EXAMPLES

[0083] The Mregs were manufactured in accordance with current GMP principles for the production of sterile medicinal products. Attention is paid at every processing step that products, materials and equipment are protected against contamination and impurities.

Example 1: Preparation of Mregs

[0084] A first Mreg preparation (“Mreg A”) was prepared according to a modified protocol of Hutchinson. Healthy human donors were subjected to leukapheresis to collect peripheral blood mononuclear cells (PBMC) which are used as starting material for Mreg generation. All donors were screened for relevant disease markers, including infectious diseases, not more than 30 days prior to leukapheresis. Donors were re-screened for the same disease markers on the day of leukapheresis. Leukapheresis was performed using the Terumo BCT Cobe Spectra device or equivalent. CD14+ monocytes were isolated from the leukapheresis product using the Miltenyi CliniMACS® system in accordance with the manufacturer's instructions.

[0085] Plastic-adherent monocytes were plated at a density of 35×10.sup.6 monocytes/175 cm.sup.2 culture flask (Cell+ T175 flask; Sarstedt) in 30 ml RPMI 1640-based medium without phenol red (Lonza) supplemented with 10% human AB serum (Lonza), 2 mM L-glutamine (Lonza), 100 U/ml penicillin, 10 μg/ml streptomycin (Lonza), and recombinant human M-CSF (RSCD Systems) at a final concentration of 5 ng/ml carried on 0.1% human serum albumin (Aventi). The cells were cultured for 6 days with complete medium exchanges on days 1, 2, and 4. On day 6, cultures were stimulated with 25 ng/ml recombinant human IFN-γ (Imukin; Boehringer Ingelheim). On day 7, the adherent cell fraction was recovered by trypsin-EDTA treatment (TrpE Express without Phenol Red; Invitrogen) followed by gentle scraping. Mregs from all flasks were pooled and resuspended in a physiological saline solution containing 5% human albumin.

[0086] A second Mreg preparation (“Mreg B”) was prepared based on the protocol described in Example 1 of PCT/EP2017/055839. Healthy human donors were subjected to leukapheresis to collect peripheral blood mononuclear cells (PBMC) which are used as starting material for Mreg generation. All donors were screened for relevant disease markers, including infectious diseases, not more than 30 days prior to leukapheresis. Donors were re-screened for the same disease markers on the day of leukapheresis. Leukapheresis was performed using the Terumo BCT Cobe Spectra device or equivalent.

[0087] CD14+ monocytes were isolated from the leukapheresis product using the Miltenyi CliniMACS® system in accordance with the manufacturer's instructions. Briefly, the leukapheresis product was transferred into a bag which was filled with PBS/EDTA-buffer containing 0.5% human serum albumin (HSA). The cells were washed once before labelling with CliniMACS® CD14 reagent according to the manufacturer's instructions. The labelled cell suspension was connected to a sterile tubing set and installed on the CliniMACS® device in order to isolate CD14+ monocytes by magnetic separation. The positively-isolated CD14+ monocyte fraction was washed with culture medium to remove the CliniMACS® separation buffer. The isolated CD14+ monocytes were re-suspended at a density of 10.sup.6 cells/ml in RPMI medium that had been supplemented with 10% male-only human AB serum (pooled and heat-inactivated), 2 mM GlutaMAX™ and 25 ng/ml recombinant human monocyte colony-stimulating factor (M-CSF). This monocyte suspension was distributed into Miltenyi® cell differentiation bags, such that each bag was seeded with 1×10.sup.6 cells/cm.sup.2 internal surface area. For cultivation, the differentiation bags were laid flat on shelves within an incubator which was set to 36-38° C., 5±1% CO.sub.2,≥60% humidity. The monocytes were allowed to precipitate onto the lower leaf of the culture bags over the course of 1 day. On day 1, the bags were inverted to allow monocytes to adhere to the opposite leaf. The cultures were maintained in the incubator for a further 5 days. To induce the final differentiation of monocytes into Mregs and to induce indoleamine 2,3-dioxygenase (IDO) expression, monocytes were stimulated by the addition of 25 ng/ml IFN-γ. After the addition of IFN-γ, the differentiation bags were inverted another time. The bags were then incubated for a further 18-24 h at 36-38° C., 5±1% CO2,≅60% humidity. On day 7, the differentiated Mregs were harvested. Cells from all parallel culture bags were pooled and washed prior to phenotypic and functional analyses.

Example 2: Phenotypic Characterization of Mregs

[0088] “Mreg A” cells obtained from Example 1 were tested for the expression of different markers. Specifically, the expression of different markers potentially having specificity for Mregs was evaluated by RT-PCR.

[0089] DHRS9: It could be shown that DHSR9 expression distinguishes human Mregs from monocyte-derived macrophages and dendritic cells. Strong DHSR9 mRNA expression was detected in Mregs, but not comparator macrophage types (n=6; mean±SD), see FIG. 2A. Immunoblotting with a custom-made rabbit anti-DHSR9 pAb demonstrated that DHSR9 protein expression distinguishes Mregs from comparator macrophages, see FIG. 2B.

[0090] CD258: It could be found that CD258 (TNFSF14) is an informative marker of human Mregs. TNFSF14 mRNA expression was detected in Mregs, but not in comparator macrophages (n=3; mean±SD), see FIG. 2C.

[0091] IDO: Mregs were found to express IDO, while comparator macrophages do not express this marker. Expression of IDO by Mregs was detected by flow cytometry, see FIG. 2H.

[0092] PAEP: Mregs were found to express PAEP, while comparator macrophages do not express this marker. FIG. 2I shows the expression of PAEP mRNA in a panel of comparator macrophages (n=3; mean±SD).

[0093] TGFβ1: Mregs were found to express TGFβ1, while comparator macrophages do not express this marker. FIG. 2K shows the expression of TGFβ1mRNA in a panel of comparator macrophages (n=3; mean±SD).

[0094] Tregs induction: Human Mregs generated from peripheral blood CD14+ monocytes were cocultured for 5 days with allogeneic T cells at a 1:2 ratio. The T cells were then analysed by flow cytometry and functional assays. T cells cocultured with allogeneic Mregs for 5 days were enriched for T cell-suppressive CD25+ FoxP3+ iTregs (FIG. 2F) which were readily discriminated from CD25+FoxP3−/low polyclonally activated T cells generated by stimulation with αCD3/αCD28 beads for 5 days. Mregs were compared to PCMO cells. The results are shown in FIG. 2M. It can be seen that the ability of inducing Tregs is limited to Mregs.

Example 3: Mregs for Treating Leg Ulcers

[0095] A 78-year old male patient suffering from peripheral artery disease (PAD) of stadium IIa in the right limb and stadium III in the left limb had undergone multiple percutaneous transluminal angioplasty (PTA) procedures and a bypass operation of the Arteria femoralis communis (AFC) and Arteria femoralis superficialis (AFS), as well as the Arteria politea left, respectively. He suffered from intensive pain episodes while walking and at rest, especially during the night.

[0096] The patient was treated with an Mreg preparation (“Mreg A”) obtained from Example 1. Specifically, 1×10.sup.7 Mregs diluted in 12 ml of 5% human serum albumin were injected into six injection sites along the lateral part of the ulcer, i.e., 2 ml per injection site. Where muscle tissue beneath the wound was accessible, the injection was given intramuscularly. Otherwise the injection was given subcutaneously. No additional treatments were performed thereafter. The wound was kept sterile with dry bandages that were changed daily.

[0097] Results: The clinical follow up of the patient shows a significant improvement in terms of wound closure over time. Clinically, night pains completely disappeared with no ischemic pain at rest. This improvement was first observed 3 months after injection of the Mregs. Walking distance improved to more than 2 km. The results of the treatment are depicted in FIG. 1.

Example 4: Mregs for Treating PAD

[0098] A 64-year old female patient suffering from diabetes mellitus with an extended arteriopathic component and peripheral artery disease (PAD) of stadium IV in the right limb was presented. She had developed a heel ulcer with a bare bone. No Arteria femoralis superficialis (AFS) or crural diffuse vessel collateralization existed anymore. No operative therapeutic interventions were possible, due to lack of crural connecting vessels. Transfemoral amputation was considered as the last treatment option.

[0099] The patient was treated with an Mreg preparation (“Mreg A”) obtained from Example 1. In total 50.000 Mregs were administered as described in Example 3 at 5 different identified (angiography) critical points. No additional treatments were performed thereafter. The wound was kept sterile and the bandages were changed daily.

[0100] Results: Clinical follow up of the patient demonstrated significant improvement of wound healing two weeks after injection. After 3 months wound healing was fully completed and the blood circulation of the right leg was compensated. The formation of additional collateral vessels was demonstrated via angiography. Transfemoral amputation was avoided.

LITERATURE

[0101] [1] Geissler E K, Hutchinson J A. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant 2013; 18: 408-15.
[2] Tang Q, Bluestone J A, Kang S M. CD4(+) Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 2012; 4: 11-21.
[3] Moreau A, Varey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res 2012; 1: 13.
[4] Broichhausen C, Riquelme P, Geissler E K, et al. Regulatory macrophages as therapeutic targets and therapeutic agent in solid organ transplantation. Curr Opin Organ Transplant 2012; 17: 332-42.
[5] Hutchinson J A, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187: 2072-8.
[6] Hutchinson J A, Riquelme P, Brem-Exner B G, et al. Tranplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21: 728-41.
[7] Hutchinson J A, Brem-Exner B G, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21: 742-54.
[8] Hutchinson J A, Roelen D, Riquelme P, et al. Preoperative treatment of a pre-sensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008; 21: 808-13.
[9] Hutchinson J A, Govert F, Riquelme P, et al. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009; 23: 140-5.